ECT for lower lip squamous cell carcinoma.
. The incidence of cutaneous SCC has increased over the last 15 years, possibly as a consequence of the ageing population and improvements in our ability to detect skin cancer at an early stage (Glass AG, Hoover RN. 1989; Motley R et al. 2002; 4. Rogers HW et al. 2006 ).
Cancer of the lip is the most common malignant lesion of the oral cavity, and approximately 90-93% of these are SCCs (Zitsch RP 3 rd et al. 1995 , Pohl MJ et al. 2000 Although considered the gold standard treatment option, radical surgery is sometimes unsuitable for patients due to their poor performance status or a refusal of surgery for personal, cosmetic and functional sequelae, or for fear of requiring additional and more radical surgical intervention.
Radiotherapy is also an effective treatment option for SCC of the lower lip, with comparable outcomes to surgical interventions for early staged cancers (Mali B et al, 2013) .
Despite radiotherapy being offerred as a primary treatment option, there may be a group of patients who are unwilling to undergo multi-staged procedures, particularly those who live in rural areas and as a result find travelling to hospitals with adequate radiotherapy services a challenge.
Several clinical studies propose electrochemotherapy (ECT) as a novel, complementary therapeutic tool to control cutaneous and subcutaneous tumors with a well-tolerated drug delivery system (Mali B et al. 2013) . Chemotherapeutic drugs with low-permeability but high cytotoxicity (e.g. bleomycin and cisplatin) are administered. Following this, a series of electrical pulses into the solid tumor are applied. This enhances the uptake of chemotherapeutic agents into cells and hence increases the cytotoxic effect to the cells (Mir LM et al. 1991; Jaroszeski MJ et al. 2000; Mir LM, 2001) . (Mir LM et al. 2006; Campana LG et al. 2009 ; Gargiulo M et al. 2010) . Non-surgical patients were defined as those with one or more of the following characteristics: poor performance status, age greater than 85 years, cardiac deficit not related to electrical malfunction, reduced lung performance, co-morbidities preventing the use of a general anaesthesia, or those patients requiring a radical surgical procedure that they were unfit to undergo. Seven out of 21 patients had been included in our previous article (Gargiulo M et al. 2012 ). For each patient, the tumor size was measured using two perpendicular diameters with a caliper, and photographs were taken prior to any intervention. Computed tomography (CT) was used to determine the stage of the tumour according to the tumour, node and metastasis (TNM) classification. ECT and patient selection were based on the European Standard Operating Procedures of Electrochemotherapy (ESOPE) guidelines (Mir LM et al. 2006) .
In this study, ECT was provided for a range of indications (Table1):
1.
Therapeutic treatment in non-surgical patients.
2.
Patients who previously underwent surgery but experienced tumour recurrence.
3.
Neo-adjuvant treatment to reduce the tumor size before surgical intervention.
4.
Palliative treatment, for symptomatic relief.
5.
Patients who declined surgical intervention.
6.
Patients who declined primary radiotherapy.
Before providing ECT, all patients had been fully informed of the specific details of their disease, about the ECT procedure and its potential risks. All patients provided written informed consent prior to treatment.
Electrochemotherapy treatment
Patients were treated under sedation with midazolam and remifentanil, and local anesthesia (2% lidocaine) was administered via a 1-to 5-mL peritumoral injection. N20 4B electrodes (IGEA S.p.A., Carpi, Italy) with linear array needles were used in all cases.
Electrodes were inserted deep into the tumor and perilesional area (1-cm margins) to secure the tumor and its margins within the electrical field generated. An intravenous bolus dose (15,000 IU/m 2 body surface area) of bleomycin was injected over a 1-minute period. Eight electrical pulses (amplitude, 1000 V/cm; duration, 100 µs) were generated and delivered at a repetition frequency of 5 kHz using the Cliniporator device (IGEA S.p.A., Carpi, Italy) with hexagonal electrodes. To ensure homogeneous distribution of the drug into the tumor volume, pulses were delivered from 8 to 28 minutes after the intravenous injection (Mir LM et al. 2006; Sersa G. 2006) .
Response assessment and follow-up.
Through measuring changes in tumor volume, the treatment response was evaluated, in accordance with the World Health Organization (WHO) guidelines (WHO, 1997).
Treatment response was evaluated 6 weeks after the administration of ECT and was classified as follows: "Objective response" (OR), defined as any decrease in tumour volume, which was further subdivided into "complete response" (CR), when the tumor was not palpable; and "partial response" (PR), a decrease in tumor volume by >50%. "No change" was defined as an increase in tumor size of <25% or a decrease of <50% in tumor volume, and finally "progressive disease" if the tumor volume increased by ≥25%.
Patients were followed-up weekly for the first 6 weeks, and then at monthly intervals. Tumors size was measured, and photographs were taken at each follow-up appointment.
In our analysis, we describe the follow-up period at three separate time points: 6 weeks, 18 months, and the patients' last-follow up appointment. (Table 3 )
Statistical analysis
IBM SPSS statistics version 24 software was used for data analysis. Categorical variables are presented as frequencies and percentages. Follow-up length is positively skewed and is presented as a median and interquartile range (IQR), whereas age is normally distributed and is presented as means and standard deviation (SD). Outcome frequencies were calculated using basic descriptive statistics.
RESULTS

Patient demographics
Between May 2009 and September 2015, a total of 21 patients with SCC of the lower lip underwent ECT; 12 were male (57.1%) and 9 were female (42.9%). The mean age was 76.0 years (SD ±8.70) with a range from 60.0 to 91.0 years (Table 1) . Non-cancerous respiratory disease constituted patients with a diagnosis of chronic obstructive pulmonary disease (n=3) or an inadequate respiratory function to undergo surgical intervention (n=1) as assessed by an independent physician. "Significant cardiovascular disease" included one, or a combination, of the following: a past medical history of ST elevated myocardial infarction (n=1), non−ST elevated myocardial infarction (n=2), coronary artery bypass surgery (n=1), stroke (n=1), current severe aortic stenosis (n=1) or bilateral carotid artery stenosis (n=1) ( Table 2 ).
In all, 76.2% (n=16/21) of patients were treated with therapeutic intent. Five underwent ECT due to the recurrence of a previous SCC at the same location. Neo-adjuvant ECT was provided to 9.5% (2/21) of patients prior to surgery; one who had no history of previous skin cancer affecting the lip, and one who had a recurrence. Palliation was the
treatment intention in 14.3% (3/21) of patients. A refusal of surgery by the patient influenced the decision to perform ECT in 23.8% (5/21) of participants (Table 1) .
Treatment response
Six weeks following ECT, an objective response (OR) was achieved in 100% of patients (21/21). In all, 71.4% (15/21) of patients experienced a CR and 28.6% (6/21) experienced a PR. No tumors showed disease progression.
After the first cycle of ECT, recurrence of the tumour was identified in 14.3% (3/21) participants. Of those who experienced recurrence, two occurred at 12 months post-ECT and one after 18 months. One patient (patient No. 3), refused additional treatment. This patient has been monitored for 49 months following the recurrence and remains in a clinically stable state with no evidence of disease progression. The other two patients (No. 9 and No. 17) underwent surgical resection of the tumour; no recurrence has been identified in either patient since.
Of the patient population undergoing ECT, 28.6% (6/21) required additional therapy.
One patient required further surgery after only a PR was achieved and the tumour recurred at 12-months' follow-up (patient No. 17 ). In addition, surgery was indicated after an initial CR but with subsequent recurrence 18-months following ECT for one patient (patient No.12), a second course of ECT was provided following a partial response in two patients (patient No.5 and No.9), and finally two patients received a neo-adjuvant course of ECT following a PR to the first course of ECT (patient No. 2 and 6) ( Table 3) . Additional treatment was successful in all cases. No patients experienced further recurrence following these additional interventions. 
Follow-up and response duration (
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DISCUSSION
ECT is a key topic in surgical oncology. Both pre-clinical and clinical trials have proved its efficacy in many different tumor types that are inoperable and/or refractory to chemotherapy and radiotherapy. The antitumoral efficacy of ECT in vitro and in vivo is due to a dual mechanism involving cell apoptosis and tissue ischemia (Cemazar M et al, 2001; Mir L. 2006) . The immunological-based mechanism of ECT-mediated anti-tumoral effects is under debate (Mir LM et al. 1992; Sersa G et al.1997; Mir LM, Orlowski S, 1999; Quaglino P et al. 2008) . ECT-induced apoptosis has been associated with aberrant mitosis (Mir L. 2006 that ECT induces ischemic necrosis of tumor cells with an anti-vascular mechanism; this is particularly useful in controlling the symptoms of bleeding nodules (Möller MG, et al, 2011) .
In contrast to other physical ablation technologies, ECT does not denature collagenic extracellular matrix proteins (Mir LM, et al, 1992; WHO,1997 ; Sersa Get al 1997; Mir LM, Orlowski S, 1999; Cemazar M, et al. 2001; Mir LM, et al, 2006; Sersa G. 2006 ; Mir L. 2006; Quaglino P et al. 2008; Snoj M, et al. 2009; Campana LG et al. 2009 We did not observe any major complications in our study either. Although some patients
reported discomfort during the application of electric pulses, the treatment was well tolerated with the administration of local anesthesia. Therefore, it is advisable to use an ECT repetition frequency of 5 kHz rather than 1 kHz, as this reduced the time required to perform the treatment, which is particularly helpful when multiple lesions need to be treated during the same session. Furthermore, each electric pulse at 5 kHz generates a single contraction of the muscle underlying the area to be treated, rather than the eight contractions during a 1-minute period when a 1-kHz frequency is used.
In 2006, ESOPE showed that ECT is a valuable treatment option for up to of 80% of cutaneous and subcutaneous metastatic nodules (Mir LM et al 2006) . 
The route of administration for the chemotherapy used in ECT has previously been under investigation. Two types of chemotherapy are typically used to treat mucosal head and neck cancers with ECT: bleomycin or cisplatin (Statigos A et al. 2015) . Similarly there has been debate concerning whether the route by which the chemotherapy is administered affects treatment efficacy. The ESOPE guidelines advise that bleomycin should be administered using the intravenous (IV) route rather than intratumourally. As part of the ESOPE study, Marty et al (Marty G et al. 2006 ) demonstrated bleomycin's superiority over cisplatin for the treat of cutaneous and subcutaneous tumour nodules in patients with skin malignancies.
Similarly, this study demonstrates that IV bleomycin is more effective than intratumoural, highlighted by the local tumour control rate of 88% using the IV route, compared with 73% when administered intratumourally. Most research using bleomycin ECT predominantly uses the IV route. Plaschke et al describe their EURECA project (Plaschke CC et al. 2017 ) . In this study, 95% of their patient cohort received IV bleomycin. As a consequence of the current evidence, we therefore replicated the methodology of previous studies and provided bleomycin to our patients using the IV route.
The treatment of primary and recurrent SCCs of the lower lip in patients considered to be unfit for surgery remains a challenge for surgeons. In the present study, we obtained OR In the present study, ECT proved to be a reliable neo-adjuvant therapy in patients with stage T3 SCC of the lower lip; higher response rates were achieved in T1-T2 tumors. The results of our study support those presented in previous studies (Bertino G et al 2016) .
When evaluating the treatment response in patients with SCC, it is important to also calculate the rate of recurrences. Our study monitored all patients for 18 months or more post- SCC of the lower lip likely affects quality of life to a substantial degree owing to the functional and cosmetic importance of the lips in daily life. In our patient sample, no delayed wound healing or infections occurred. All lesions treated with ECT healed without any noticeable asymmetry or keloid scar formation. In particular, we noticed that the healing occurred by secondary intention which helped to maintain the continence of the mouth because of tangential scar retractions (Fig 1) However, evidence has shown that in patients will full thickness lesions, wide loss of tissue with fistula formation or labial incompetence can occur (Bertino G et al 2016) . An excellent functional and cosmetic result can be appreciated following ECT, even for large tumors that otherwise would have required extensive surgery with total lip excision and free tissue transfer to reconstruct the defect ( Fig   2) . Unfortunately, we did not formally assess the functional and cosmetic result with any validated questionnaire. All patients were treated under local anaesthetic with or without sedation. This demonstrates an opportunity to offer an effective and validated treatment option for patients who cannot or are not willing to undergo surgical excision under general anaesthesia. This treatment improves the quality of life of patients with SCC of the lower lip, not only by conserving the anatomical integrity of the lips, but by minimizing pain and allowing patients to return to their normal activities (Bertino G et al 2016) (Fig 3) . 
